OPKO Health (NASDAQ:OPK) (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.
In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States. BioReference offers routine clinical testing, women’s health panels, oncology diagnostics, genetic and genomic assays, and esoteric testing to hospitals, physicians and clinical research organizations. During the COVID-19 pandemic, the laboratory network expanded testing capacity to meet growing public health needs. Beyond the U.S., OPKO’s diagnostic operations extend into Latin America, serving customers in Mexico, Brazil and Argentina.
OPKO’s Pharma Services & Products segment is dedicated to the development, licensing and commercialization of innovative therapeutics. The company’s marketed portfolio includes Rayaldee®, an FDA-approved treatment for secondary hyperparathyroidism in adults with stage 3–4 chronic kidney disease. OPKO also advances a pipeline of small molecules, biosimilars and novel biologics targeting metabolic disorders, endocrinology and oncology. Strategic collaborations and in-licensing arrangements bolster the company’s research capabilities and expand its product offerings.
Founded in 2007, OPKO has grown through strategic acquisitions—most notably the 2015 purchase of BioReference Laboratories—and partnerships with academic and industry leaders. Under the leadership of Chairman and CEO Dr. Phillip Frost, a physician-scientist and experienced biotech entrepreneur, the company emphasizes an integrated approach that combines advanced diagnostics with precision therapeutics. OPKO continues to pursue geographic expansion and pipeline diversification to meet evolving healthcare demands worldwide.
